Andrew Rzemien
About Andrew Rzemien
Andrew Rzemien is a Research Associate specializing in Immunology and Cell Therapy at Tessera Therapeutics in Somerville, Massachusetts. He has a background in cellular and molecular biology, gene therapy, and immunology, and holds a Bachelor of Science in Biochemistry from the University of Vermont.
Work at Tessera Therapeutics
Andrew Rzemien has been employed at Tessera Therapeutics as a Research Associate in Immunology and Cell Therapy since 2022. His role involves contributing to research initiatives focused on innovative therapies in the field of immunology and cell therapy. The company is located in Somerville, Massachusetts, and is known for its work in gene therapy and advanced treatment modalities.
Previous Experience at RootPath
Prior to joining Tessera Therapeutics, Andrew Rzemien worked at RootPath as a Research Associate from 2021 to 2022. During his tenure at RootPath, he gained valuable experience in research methodologies and techniques relevant to his field, further enhancing his expertise in immunology and cell therapy.
Education and Expertise
Andrew Rzemien earned a Bachelor of Science degree in Biochemistry from the University of Vermont, where he studied from 2017 to 2020. His educational background provides a solid foundation in cellular and molecular biology, gene therapy, and immunology, which are critical to his current research focus.
Research Interests
Andrew Rzemien has a keen interest in several areas of biomedical research, including immuno-oncology, neurological diseases, and autoimmune diseases. These interests align with his professional work and contribute to his ongoing development as a research associate in the field of immunology and cell therapy.
Background in Cellular and Molecular Biology
Andrew Rzemien possesses a diverse background in cellular and molecular biology. This knowledge base supports his work in gene therapy and immunology, allowing him to engage effectively in research that addresses complex biological questions and therapeutic challenges.